Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Ray-Coquard

Showing results (451-460 of 509) with videos related to

Pageof 51
Sort By:
Cancers|March 10, 2022
Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 TrialJean-David Fumet, Emilie Lardenois, Isabelle Ray-Coquard, et al.
Breast (Edinburgh, Scotland)|January 11, 2023
Contraception in breast cancer survivors from the FEERIC case-control study (performed on behalf of the Seintinelles research network)Clara Sebbag, Christine Rousset-Jablonski, Florence Coussy, et al.
Cancers|February 5, 2021
Bringing Onco-Innovation to Europe's Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised MedicineDenis Horgan, Gennaro Ciliberto, Pierfranco Conte, et al.
Nature Communications|July 16, 2024
Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinomaOlivia Le Saux, Maude Ardin, Justine Berthet, et al.
BMC Cancer|July 22, 2024
ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancerAlexandra Leary, Purificación Estévez-García, Renaud Sabatier, et al.
The Lancet Regional Health. Europe|February 22, 2024
Management of patients with rare adult solid cancers: objectives and evaluation of European reference networks (ERN) EURACANJean-Yves Blay, Paolo Casali, Isabelle Ray-Coquard, et al.
Lancet (London, England)|December 4, 2023
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trialAna Oaknin, Laurence Gladieff, Jerónimo Martínez-García, et al.
Cancer Discovery|November 15, 2018
<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian CarcinomaKevin K Lin, Maria I Harrell, Amit M Oza, et al.
The Lancet. Oncology|August 30, 2024
Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroupCarien L Creutzberg, Jae-Weon Kim, Gemma Eminowicz, et al.
Gynecologic Oncology|January 24, 2020
Low-grade serous ovarian cancer: State of the scienceBrian Slomovitz, Charlie Gourley, Mark S Carey, et al.
Pageof 51

Showing results (451-460 of 509) with videos related to

Sort By:
Pageof 51
Cancers|March 10, 2022
Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 TrialJean-David Fumet, Emilie Lardenois, Isabelle Ray-Coquard, et al.
Breast (Edinburgh, Scotland)|January 11, 2023
Contraception in breast cancer survivors from the FEERIC case-control study (performed on behalf of the Seintinelles research network)Clara Sebbag, Christine Rousset-Jablonski, Florence Coussy, et al.
Cancers|February 5, 2021
Bringing Onco-Innovation to Europe's Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised MedicineDenis Horgan, Gennaro Ciliberto, Pierfranco Conte, et al.
Nature Communications|July 16, 2024
Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinomaOlivia Le Saux, Maude Ardin, Justine Berthet, et al.
BMC Cancer|July 22, 2024
ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancerAlexandra Leary, Purificación Estévez-García, Renaud Sabatier, et al.
The Lancet Regional Health. Europe|February 22, 2024
Management of patients with rare adult solid cancers: objectives and evaluation of European reference networks (ERN) EURACANJean-Yves Blay, Paolo Casali, Isabelle Ray-Coquard, et al.
Lancet (London, England)|December 4, 2023
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trialAna Oaknin, Laurence Gladieff, Jerónimo Martínez-García, et al.
Cancer Discovery|November 15, 2018
<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian CarcinomaKevin K Lin, Maria I Harrell, Amit M Oza, et al.
The Lancet. Oncology|August 30, 2024
Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroupCarien L Creutzberg, Jae-Weon Kim, Gemma Eminowicz, et al.
Gynecologic Oncology|January 24, 2020
Low-grade serous ovarian cancer: State of the scienceBrian Slomovitz, Charlie Gourley, Mark S Carey, et al.
Pageof 51